Pharmaceutical - Actelion


Current filters:


Popular Filters

Actelion says PAH drug Opsumit now available in USA

Actelion says PAH drug Opsumit now available in USA


Actelion has confirmed that Opsumit 10mg, an oral, dual endothelin receptor antagonist for pulmonary…

ActelionMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonary

Positive EMA/CHMP opinions for Actelion and Lundbeck

Positive EMA/CHMP opinions for Actelion and Lundbeck


At its October month-end meeting, the European Medicines Agency’s Committee for Medicinal Products…

ActelionBiotechnologyBrintellixEuropeLundbeckNeurologicalOpsumitPharmaceuticalRegulationRespiratory and Pulmonary

Actelion to start Phase III studies into cadazolid for C. difficile related diarrhea


Swiss biotech firm Actelion (SIX: ATLN) will initiate a Phase III clinical development program to assess…

ActelionAntibiotics and Infectious diseasescadazolidEuropePharmaceuticalResearchVancomycin

Actelion's Opsumit for PAH shows reduction in morbidity and mortality


Swiss biotech firm Actelion (SIX: ATLN) has announced key morbidity and mortality data in pulmonary arterial…


FDA staffers back riociguat approval, but with modified dose


On Tuesday (August 6), the US Food and Drug Administration's Renal Drugs Advisory Committee will discuss…

ActelionAdempasBayerNorth AmericaOpsumitPharmaceuticalRegulationRespiratory and PulmonaryriociguatTracleer

US pulmonologists views on PAH prescribing options


US pulmonologists surveyed by health care advisory firm Decision Resources consider a drug's effect on…

ActelionBayerMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonaryriociguat

New Zealand updates on Tracleer and sildenafil listing


New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

ActelionArrow PharmaceuticalsAsia-PacificPharmaceuticalPricingRegulationRespiratory and PulmonarysildenafilTracleer

Actelion announces cost saving initiative; Ipsen to hang on to Dreux


Europe largest biotech firm, Actelion (SIX: ATLN) this morning said it has launched a cost saving initiative…


Auxilium and Actelion partner on Xiaflex


biotech firm, have entered into a long-term partnership for the development, supply and commercialization…

ActelionAuxilium PharmaceuticalsBiotechnologyLicensingPharmaceuticalRare diseasesXiaflex

Clazosentan for traumatic brain injury shows promise in animals


A new drug is showing promise in shielding against the harmful effects of traumatic brain injury (TBI)…


Actelion pulls out of Trophos option


Switzerland-based Actelion (SIX: ATLN), Europe’s biggest biotech company, says that it has decided…

ActelionBiotechnologyLicensingMergers & AcquisitionsolesoximePharmaceuticalRare diseasesTrophos

Executive appointments at Merck & Co, Actelion and Jazz Pharma


US drug giant Merck & Co (NYSE: MRK) has appointed Cuong Viet Do as chief strategy officer, effective…

ActelionBiotechnologyJazz PharmaceuticalsManagementMerck & CoPharmaceutical

Novartis cancer drug imatinib shows efficacy in PAH


Swiss drug major Novartis (NOVN: VX) yesterday announced new data today at the European Respiratory Society…

ActelionCardio-vascularImatinib MesylateNovartisPharmaceuticalResearchRespiratory and PulmonaryTracleer

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top